Barrett is taking over as CEO of the uro-oncology specialist at a time when it is working on a rolling NDA that could lead to its first drug approval.“It’s the attraction of being able to build something from scratch and really have an impact versus dealing frankly with a big company where you can have an impact ... but it's a lot harder when you go through all the governances.
“We are talking to companies about collaborations for potentially partnering on taking some small molecules and using them with the technology.”Greater use of the gel technology is one way UroGen may expand its pipeline under Barrett’s leadership beyond the urothelial carcinoma, bladder cancer and overactive bladder assets currently in clinical testing. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end." Novartis appoints ad interim leader for its Global Drug Development organization. It's difficult to move a big ship,” Barrett said.“There's nothing that we've seen so far that makes us think that you can't use this [gel] technology across many molecules. Barrett is a US citizen and has lived and worked in the US and Europe.
After spending almost nine years at Pfizer and 13 years at Johnson & Johnson earlier in her career, Barrett had an eye on moving away from Big Pharma when the Novartis job became available. Bryant Aaron. She will report to Vas Narasimhan, CEO, Novartis, and will join the Executive Committee on January 1, 2019. As CEO of UroGen, Barrett will oversee the rolling FDA submission of lead candidate UGN-101, a formulation of mitomycin that uses the company’s reverse thermal gel technology to treat low-grade upper tract urothelial carcinoma.The fact Barrett can envisage strategies that will have a huge effect on the future of UroGen is part of the appeal of the new role. Director, Leadership Development & Capabilities at Novartis Oncology University of South Florida - College of Business Administration View profile View profile badges The Novartis Leadership Development Program (NLDP) is an entry-level, 24-months assignment rotation program designed to provide recent graduates accelerated training in the Pharmaceutical Commercial … She obtained an MBA in Marketing from the Saint Joseph's University in Philadelphia and a BSc in Business Administration from the University of Louisiana.This site is intended for a global audience.Vasant (Vas) Narasimhan, designated CEO of Novartis, said: "Liz is a highly accomplished and recognized oncology and people leader with an impressive record of building successful business organizations in the US, Europe and globally.
In parallel, Barrett will work to identify additional applications of the reverse thermal gel technology—which increases body cavity dwell time to boost efficacy—and bring other technologies and assets on board.The other way is to bring in uro-oncology assets unrelated to the gel technology. Liz Barrett will be stepping down as CEO of Novartis Oncology … He'll come off of the executive committee by the end of the year and fully hand off the reins in early 2018.Now, Gilead and Novartis are the only two commercial CAR-T companies, with many others pursuing the technology in the clinic. Germo Gericke, M.D., was appointed Head of Research and Development of Advanced Accelerator Applications (AAA), a Novartis company in 2018.Germo continues his role as a member of the Oncology Development Leadership Team at Novartis. ECN members are chosen by the Board of Directors. Before joining Pfizer in 2009, she worked at Cephalon, Inc. and Johnson & Johnson. Basel, January 11, 2018 - Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018. "Prior to Merck, Strigini served as president, international for UCB and as a VP of international marketing for GlaxoSmithKline, according to his LinkedIn page.Just before Strigini joined Novartis, the company agreed to its massive asset swap with GSK, offloading its vaccine programs—besides flu—in exchange for Glaxo's cancer offerings. ""I wish him the best for his future," Jimenez added.Novartis didn't give any indication how it plans to fill the role, saying only that it will "announce his successor in due time."